O Brien Greene & Co. Inc Sells 88 Shares of Johnson & Johnson (NYSE:JNJ)

O Brien Greene & Co. Inc trimmed its stake in Johnson & Johnson (NYSE:JNJ) by 1.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,908 shares of the company’s stock after selling 88 shares during the quarter. O Brien Greene & Co. Inc’s holdings in Johnson & Johnson were worth $999,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of JNJ. IFS Advisors LLC lifted its holdings in Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after purchasing an additional 100 shares during the last quarter. Highline Wealth Partners LLC acquired a new stake in Johnson & Johnson during the 3rd quarter worth approximately $31,000. Bay Harbor Wealth Management LLC acquired a new stake in Johnson & Johnson during the 4th quarter worth approximately $32,000. RPg Family Wealth Advisory LLC acquired a new stake in Johnson & Johnson during the 3rd quarter worth approximately $35,000. Finally, Activest Wealth Management acquired a new stake in Johnson & Johnson during the 3rd quarter worth approximately $40,000. 69.55% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts recently weighed in on JNJ shares. Guggenheim lifted their price target on Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a report on Monday, February 3rd. Raymond James dropped their price target on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Argus raised Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Bank of America dropped their price objective on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a report on Thursday, January 23rd. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a report on Wednesday, February 19th. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $170.67.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $162.35 on Monday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The stock has a market capitalization of $390.87 billion, a P/E ratio of 24.41, a price-to-earnings-growth ratio of 2.56 and a beta of 0.52. The stock has a fifty day moving average of $148.93 and a 200-day moving average of $155.86.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. During the same quarter in the previous year, the firm earned $2.29 EPS. Johnson & Johnson’s revenue was up 5.3% on a year-over-year basis. On average, sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.06%. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Insider Buying and Selling

In other news, Director Mark A. Weinberger acquired 1,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. This represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.